Search Results - "Parham, Laura"

Prospective Validation of HLA-DRB107:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury by SCHAID, Daniel J, SPRAGGS, Colin F, GOSS, Paul E, MCDONNELL, Shannon K, PARHAM, Laura R, COX, Charles J, EJLERTSEN, Bent, FINKELSTEIN, Dianne M, RAPPOLD, Erica, CURRAN, Joan, CARDON, Lon R

“…Liver injury is a serious adverse event leading to permanent discontinuation of lapatinib in affected patients. This study aimed to validate previously…”
Get full text

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis by Condreay, Lynn D., Parham, Laura R., Qu, Xiaoyan A., Steinfeld, Jonathan, Wechsler, Michael E., Raby, Benjamin A., Yancey, Steven W., Ghosh, Soumitra

“…Treatment of patients with the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) with mepolizumab, a monoclonal antibody to interleukin-5…”
Get full text

Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms by Parham, Laura R, Briley, Linda P, King, Karen S, Byrne, Julie, Rappold, Erica, Goss, Paul E, Spraggs, Colin F

“…Rash is a common side effect of lapatinib treatment. Since human leukocyte antigen ( ) alleles have been implicated in multiple drug-induced cutaneous…”
Get full text

Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir by Patel, Parul, Xue, Zhengyu, King, Karen S, Parham, Laura, Ford, Susan, Lou, Yu, Bakshi, Kalpana K, Sutton, Kenneth, Margolis, David, Hughes, Arlene R, Spreen, William R

“…Cabotegravir is an HIV integrase inhibitor in clinical development with both oral and long-acting (LA) injectable formulations. Cabotegravir is primarily…”
Get full text

Evaluation of pro-apoptotic BIM gene loss of function on lapatinib efficacy in patients with metastatic breast cancer (MBC) and in HER2-amplified cell lines by Spraggs, Colin F., Briley, Linda P, King, Karen S, Zhou, Felix, Qin, Sherry, Qin, Crystal Ying, Russo, Mark W., Parham, Laura Rae

“…Abstract only…”
Get full text

Prospective Validation of HLA-DRB1 07:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury by Schaid, Daniel J., Spraggs, Colin F., McDonnell, Shannon K., Parham, Laura R., Cox, Charles J., Ejlertsen, Bent, Finkelstein, Dianne M., Rappold, Erica, Curran, Joan, Cardon, Lon R., Goss, Paul E.

“…Purpose Liver injury is a serious adverse event leading to permanent discontinuation of lapatinib in affected patients. This study aimed to validate previously…”
Get full text

VEGF polymorphism may be associated with overall survival in lapatinib-treated breast cancer patients with brain metastases by Spraggs, Colin F., Li, Li, Briley, Linda P., Joshi, Alaknanda, Florance, Allison M., King, Karen, Parham, Laura R

“…Abstract only 10532 Background: Lapatinib is a dual HER2/EGFR tyrosine kinase inhibitor (TKI) approved in combination with capecitabine or letrozole for…”
Get full text

HLA-DRB1 07:01 biomarker characterization of hepatotoxicity during lapatinib combination therapies in ALTTO by Spraggs, Colin F., Parham, Laura Rae, Warren, Liling, Williams, Lisa Simone, Briley, Linda P, Fraser, Dana, Jiang, Zefei, Aziz, Zeba, Tong, Zhongsheng, Moodley, Shun Devan, Mehta, Ajay O., Jackson, Nicola, Byrne, Julie, Andersson, Michael, Toi, Masakazu, Harris, Lyndsay, Gralow, Julie, Crescenzo, Rocco, Armour, Alison A.

“…Abstract only…”
Get full text